You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 13, 2024

CLINICAL TRIALS PROFILE FOR TEMOZOLOMIDE


✉ Email this page to a colleague

« Back to Dashboard


505(b)(2) Clinical Trials for Temozolomide

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
New Combination NCT00876993 ↗ Study of Irinotecan and Bevacizumab With Temozolomide in Refractory/Relapsed Central Nervous System (CNS) Tumors Completed Brain Tumor Alliance Phase 1 2008-09-01 Bevacizumab, irinotecan, and temozolomide are three agents shown to have promising activity in a variety of central nervous system tumors. No prospective studies have been published or are currently in progress within the major consortiums with this combination of drugs. Brain tumors are the second most common cause of cancer in pediatrics and the leading cause of cancer death in children. For children with High Grade Gliomas or with relapsed/refractory brain tumors, new agents in new combinations are needed. Historical data shows that newly diagnosed high grade gliomas 5 year progression free survival is 28-42%. Recurrent malignant gliomas median survival is 3-9 months. Recurrent medulloblastoma's 2 years survival is 9%. This study is a phase I study designed to provide an objective observation of toxicity and establish a maximum tolerated dose of this combination. In addition, this study will observe the response of children with relapsed or refractory central nervous system tumors.
New Combination NCT00876993 ↗ Study of Irinotecan and Bevacizumab With Temozolomide in Refractory/Relapsed Central Nervous System (CNS) Tumors Completed The V Foundation Phase 1 2008-09-01 Bevacizumab, irinotecan, and temozolomide are three agents shown to have promising activity in a variety of central nervous system tumors. No prospective studies have been published or are currently in progress within the major consortiums with this combination of drugs. Brain tumors are the second most common cause of cancer in pediatrics and the leading cause of cancer death in children. For children with High Grade Gliomas or with relapsed/refractory brain tumors, new agents in new combinations are needed. Historical data shows that newly diagnosed high grade gliomas 5 year progression free survival is 28-42%. Recurrent malignant gliomas median survival is 3-9 months. Recurrent medulloblastoma's 2 years survival is 9%. This study is a phase I study designed to provide an objective observation of toxicity and establish a maximum tolerated dose of this combination. In addition, this study will observe the response of children with relapsed or refractory central nervous system tumors.
New Combination NCT00876993 ↗ Study of Irinotecan and Bevacizumab With Temozolomide in Refractory/Relapsed Central Nervous System (CNS) Tumors Completed V Foundation Phase 1 2008-09-01 Bevacizumab, irinotecan, and temozolomide are three agents shown to have promising activity in a variety of central nervous system tumors. No prospective studies have been published or are currently in progress within the major consortiums with this combination of drugs. Brain tumors are the second most common cause of cancer in pediatrics and the leading cause of cancer death in children. For children with High Grade Gliomas or with relapsed/refractory brain tumors, new agents in new combinations are needed. Historical data shows that newly diagnosed high grade gliomas 5 year progression free survival is 28-42%. Recurrent malignant gliomas median survival is 3-9 months. Recurrent medulloblastoma's 2 years survival is 9%. This study is a phase I study designed to provide an objective observation of toxicity and establish a maximum tolerated dose of this combination. In addition, this study will observe the response of children with relapsed or refractory central nervous system tumors.
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for Temozolomide

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00003062 ↗ Temozolomide in Patients With Progressive or Recurrent Non-small Cell Lung Cancer Completed European Organisation for Research and Treatment of Cancer - EORTC Phase 2 1997-07-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effect of temozolomide in patients with progressive or recurrent stage IV non-small cell lung cancer, with or without brain metastases, who have not been treated for metastatic disease with chemotherapy.
NCT00003176 ↗ Temozolomide and Carmustine in Treating Patients With Anaplastic Glioma Completed National Cancer Institute (NCI) Phase 2 1998-03-25 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of temozolomide and carmustine in treating patients with anaplastic glioma.
NCT00003176 ↗ Temozolomide and Carmustine in Treating Patients With Anaplastic Glioma Completed North American Brain Tumor Consortium Phase 2 1998-03-25 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of temozolomide and carmustine in treating patients with anaplastic glioma.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Temozolomide

Condition Name

Condition Name for Temozolomide
Intervention Trials
Glioblastoma 218
Glioblastoma Multiforme 129
Brain and Central Nervous System Tumors 89
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Temozolomide
Intervention Trials
Glioblastoma 463
Glioma 195
Central Nervous System Neoplasms 113
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Temozolomide

Trials by Country

Trials by Country for Temozolomide
Location Trials
Spain 98
Japan 75
Netherlands 55
Switzerland 55
Belgium 52
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Temozolomide
Location Trials
California 196
Texas 173
New York 165
North Carolina 151
Ohio 146
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Temozolomide

Clinical Trial Phase

Clinical Trial Phase for Temozolomide
Clinical Trial Phase Trials
Phase 4 5
Phase 3 76
Phase 2/Phase 3 19
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Temozolomide
Clinical Trial Phase Trials
Completed 405
Recruiting 170
Not yet recruiting 110
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Temozolomide

Sponsor Name

Sponsor Name for Temozolomide
Sponsor Trials
National Cancer Institute (NCI) 236
Schering-Plough 37
Merck Sharp & Dohme Corp. 36
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Temozolomide
Sponsor Trials
Other 1205
Industry 487
NIH 249
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.